Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1993 Aug;68(2):399-402.
doi: 10.1038/bjc.1993.348.

p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance

Affiliations
Free PMC article
Comparative Study

p53 immunoreaction in endoscopic biopsy specimens of colorectal cancer, and its prognostic significance

A Yamaguchi et al. Br J Cancer. 1993 Aug.
Free PMC article

Abstract

The expression of p53 protein was immunohistochemically studied in formalin-fixed paraffin-embedded biopsy specimens of 203 colorectal carcinomas by use of a monoclonal antibody specific for the p53 protein. PAb1801. p53 protein expression with its reactivity localised in nuclei was found in 121 (59.6%) of the cancers. There was no correlation of p53 immunoreactivity with histological classification, wall invasion, lymphatic invasion, venous invasion, lymph node metastases, or peritoneal metastases. p53-positive cancers were more frequently associated with liver metastasis than p53-negative ones. Patients with p53-positive tumours had significantly poorer prognoses than those with p53-negative tumours. The 5 year survival rate was 58.1% for patients with p53-positive tumours, and 76.3% for those with p53-negative tumours. In Dukes' stage C tumours, an especially good correlation was found between p53 immunoreactivity and prognosis. In addition, patients with p53-positive tumours had higher recurrence rates. The results indicate that p53 immunoreactivity may be a useful prognostic marker of colorectal cancers.

PubMed Disclaimer

References

    1. Nature. 1979 Mar 15;278(5701):261-3 - PubMed
    1. Cancer. 1992 Dec 15;70(12):2778-84 - PubMed
    1. J Natl Cancer Inst. 1982 Jul;69(1):15-22 - PubMed
    1. Proc Natl Acad Sci U S A. 1982 Oct;79(20):6309-12 - PubMed
    1. EMBO J. 1983;2(7):1041-7 - PubMed

Publication types

MeSH terms

Substances